PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer 18F-FDG. 18F-AlF-NOTA-PCP2 uptake strongly correlated with PD-L1 levels, ...

A post hoc analysis of the BEATcc trial showed that atezolizumab plus chemotherapy and bevacizumab provided clinical benefit ...

About APVO711. Novel Mechanism: APVO711 is a bispecific antibody targeting PD-L1 × CD40-combining checkpoint inhibition with immune activation in a single molecule. Designed for Potency: Unlike ...

PD-L1 is a critical biomarker for potential response to anti-PD-1 therapies, which are revolutionizing the treatment of cancer. Pathology labs play an important role in informing treatment decisions.

Additionally, six PD-L1–resistant patients with stable disease remain on treatment past 12 or more weeks, with tumor reductions ranging from 0% to 17%, suggesting durable disease control in a subset ...

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1 ...

The investigational PD-1/VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced PD-L1-positive NSCLC.

The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.The agent (Tecentriq Hybreza, Genentech) is the first subcutaneous anti-PD-L1 cancer immunotherapy approved in the ...